Telomerase reverse transcriptase (TERT) promoter mutations are most commonly observed in malignant melanoma, uroepithelial bladder cancer, glioblastoma, mucinous liposarcoma, as well as in certain skin cancer and medulloblastoma subtypes. This evidence concerns the gene TERT and melanoma.